Jetzt bei Plus500 CFDs auf die weltweit gefragtesten Basiswerte wie Aktien, Indizes oder Kryptowährungen entdecken!5 -W-
24.04.2008 12:35:00

Smith & Nephew Endoscopy Launches the FOOTPRINT PK Suture Anchor for Shoulder Repair

ANDOVER, Mass., April 24 /PRNewswire-FirstCall/ -- Smith & Nephew's Endoscopy Division today announced the launch of the FOOTPRINT PK Suture Anchor, a system used to attach rotator cuff tissue to bone in the shoulder. The anchor is among products featured at the Arthroscopy Association of North America (AANA) Spring Meeting, which began today in Washington, D.C.

The objective during rotator cuff repair is to return the soft tissue to its original anatomic attachment site. Unlike early single row suture anchor techniques, which employed single-point re-attachment, the "footprint repair" approach uses multiple anchors in two rows, often with suture bridges that provide greater tissue-to-bone attachment (see attached).

Early approaches to cuff repair included transosseous tunnel repairs, which are still done today in some medical practices. During this procedure, the surgeon drills bone tunnels through the humeral head and laces suture through them. Smith & Nephew Endoscopy's FOOTPRINT PK Suture Anchor delivers a Transosseous Equivalent (TOE) repair without the need for drilling transosseous bone tunnels.

Its two-piece design allows for the shell of the anchor to be tapped into place. Then, independent of implantation, an inner plug is advanced, which secures the sutures running from the other anchor rows.

"The FOOTPRINT PK Suture Anchor enables surgeons to precisely apply the desired amount of suture tension that is necessary to maximize the construct strength on a case-by-case basis," said Dr. Nikhil Verma, an orthopaedic surgeon and sports medicine specialist at Midwest Orthopaedics at Rush University Medical Center in Chicago. "The suture tension can be adjusted even after the anchor is implanted."

The anchor design enables the surgeon to adjust the tension of the suture bridges, so the final fixation is set exactly as the surgeon wishes. Unlike anchors where the tension is set before anchor implantation, the surgeon knows exactly how much tension is present upon completion.

"In designing the FOOTPRINT PK Suture Anchor, our engineers listened to the concerns of surgeons who want to preserve healthy tissue, achieve optimal fixation and help their patients resume the activities they enjoy," said Mike Frazzette, President of Smith & Nephew Endoscopy. "We are pleased to showcase this device during the AANA Meeting, where we are able to demonstrate the technology to so many of our surgeon customers."

Contact: Joe Metzger Vice President, Corporate Communications Smith & Nephew Endoscopy (978) 749-1330 joe.metzger@smith-nephew.com About Us

Smith & Nephew is a global medical technology business, specialising in Orthopaedic Reconstruction, Orthopaedic Trauma and Clinical Therapies, Endoscopy and Advanced Wound Management products. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.

Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company operates in 32 countries around the world. Annual sales in 2007 were nearly $3.4 billion.

Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. In particular, statements regarding planned growth in our business and in our operating margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward- looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.

All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Analysen zu Smith & Nephew plcmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Smith & Nephew plc 11,66 -0,72% Smith & Nephew plc

Indizes in diesem Artikel

FTSE 100 8 325,95 -0,40%
FTSE Allshare 4 548,88 -0,30%